Equillium Continues Graft-Versus-Host Disease Trial, Pauses 2 Others

Equillium has halted two clinical trials of its lead drug candidate out of an “abundance of caution” related to the coronavirus outbreak but continues to enroll in a third, which is evaluating the antibody as a treatment for acute graft-versus-host disease.